Reading LEXX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LEXX free→Reading LEXX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LEXX free→QuarterlyIQ Insights · LEXX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing Nasdaq Bid Price Deficiency Notice On February 4, 2026, Lexaria Bioscience Corp. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing o…
Entry into a Material Definitive Agreement. On December 14, 2025, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold to the investors (i) in a registered direct offering, 2,661,600 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.315 per share, and (ii) in a…
Unregistered Sale of Equity Securities. The applicable information set forth in
Entry into a Material Definitive Agreement. On September 26, 2025, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold to the investors (i) in a registered direct offering, 2,666,667 shares (the “Shares”) of Common Stock, par value $0.001 per share of the Company (the “Common Stock”) at a price of $1.50 per share, and (ii) in a…
Unregistered Sale of Equity Securities. The applicable information set forth in
Termination of a Material Definitive Agreement. Effective September 19, 2025, Lexaria Bioscience Corp. (the “Company”) terminated the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC (the “Agent”), as originally entered into on August 21, 2024 (the full text having been filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed August 22, 2024) and, as amended by Amendment No. 1 on February 5, 2025 (the full text having been filed as Exhibit 10.1 to…
Entry into a Material Definitive Agreement. On April 24, 2025, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with a single institutional investor, pursuant to which the Company agreed to issue and sell to the investor in a registered direct offering (i) 1,925,000 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a purchase price of $1.00 per share, and (ii) pre-fu…
This Current Report on Form 8-K does not constitute an offer to sell any securities or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Entry into a Material Definitive Agreement. On February 5, 2025, Lexaria Bioscience Corp. (the “Company”) and JonesTrading Institutional Services LLC (the “Agent”) entered into Amendment No. 1 (the “Amendment”) to the Capital on Demand™ Sales Agreement between the parties originally entered into on August 21, 2024 (the “Original Agreement” and, as amended by the Amendment, the “Sales Agreement”). The Amendment amends the Original Agreement to (i) amend the defined term “Registration Statement…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.